New Parkinson’s drug found effective
A study conducted on 404 patients at several U.S. sites has determined that a new drug called Rasagiline effectively treats early-stage Parkinsons disease. The study was reported in the December Archives of Neurology.
“These findings are especially important since hopes for treating Parkinsons with fetal cells were recently dashed,” said Technion-Israel Institute of Technology Professor Moussa Youdim, who developed Rasagiline with Prof. John Finberg of the Department of Pharmacology at the Technion.
The study was conducted as part of the clinical trials for FDA approval. Rasagiline is now in the last stage of the approval process with a decision expected later this year. Teva Pharmaceuticals will then market the new drug.
Research participants were randomized in the double-blind, placebo-controlled study. Participants were given 1 or 2 milligrams a day for one week, followed by a 25-week maintenance period.
The treatments effectiveness was measured by Unified Parkinsons Disease Rating Scale (UPDR) and compared with the control group that received a placebo. The group that received 1 milligram showed an improvement of 4.2 UPDR units on average. Those who received 2 milligrams showed an improvement of 3.56 UPDR units.
The report called for further study to evaluate Rasagilines long-term effects on the progression of the disease. This is now in progress.
Prof. Youdim heads the Eve Topf Neuro-Degenerative Disease Research and Teaching Center at the Faculty of Medicine at the Technion, where he develops a variety of drugs for neurodegenerative diseases. As early as 1975, Prof. Youdim and colleagues introduced I-Deprenyl (Selegiline), a drug that has been shown to slow the progress of Parkinsons disease.
Contact: Martha Molnar
e-mail: martha@ats.org
Media Contact
All latest news from the category: Health and Medicine
This subject area encompasses research and studies in the field of human medicine.
Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…